Search

Your search keyword '"Mercedes Delgado-Garcia"' showing total 2 results
Start Over Author "Mercedes Delgado-Garcia"
2 results on '"Mercedes Delgado-Garcia"'

1. Multicenter Evaluation of the Idylla GeneFusion in Non-Small-Cell Lung Cancer

Author

Thomas Depoilly, Simon Garinet, Léon C. van Kempen, Ed Schuuring, Sergi Clavé, Beatriz Bellosillo, Cristiana Ercolani, Simonetta Buglioni, Janna Siemanowski, Sabine Merkelbach-Bruse, Verena Tischler, Melanie-Christin Demes, Henry Paridaens, Catherine Sibille, Vincent Thomas de Montpreville, Etienne Rouleau, Artur Bartczak, Monika Pasieka-Lis, Ryan Yee Wei Teo, Khoon Leong Chuah, Marta Barbosa, Carlos Quintana, Michele Biscuola, Mercedes Delgado-Garcia, Davide Vacirca, Alessandra Rappa, Matthew Cashmore, Matthew Smith, Piotr Jasionowicz, Adam Meeney, Patrice Desmeules, Benoit Terris, Audrey Mansuet-Lupo, Targeted Gynaecologic Oncology (TARGON), and Damage and Repair in Cancer Development and Cancer Treatment (DARE)

Subjects
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins, Mutation, Molecular Medicine, Humans, Receptor Protein-Tyrosine Kinases, Protein-Tyrosine Kinases, In Situ Hybridization, Fluorescence, Pathology and Forensic Medicine, Retrospective Studies
Abstract

Targeted therapy in lung cancer requires the assessment of multiple oncogenic driver alterations, including fusion genes. This retrospective study evaluated the Idylla GeneFusion prototype, an automated and ease-of-use (

Published
2022

2. Clinical Performance Evaluation of the Idylla™ Egfr Mutation Test on Formalin-Fixed Paraffin-Embedded Tissue of Non-Small Cell Lung Cancer

Author

Mercedes Delgado-Garcia, Birgit Weynand, Lourdes Gómez Izquierdo, María José Hernández Barrera, Ángela María Blanco Lobo, Mar Varela Rodríguez, Xavier Matias Guiu, Ernest Nadal, Bélgica Márquez Lobo, Ana Alarcão, Enrique de Álava Casado, Michele Biscuola, and Mercedes Delgado-García

Abstract

Background: detection of epidermal growth factor receptor (EGFR) mutations in exons 18-21 is recommended in all patients with advanced Non-small-cell lung carcinoma due to the demonstrated efficiency of the standard therapy with tyrosine kinase inhibitors in EGFR-mutated patients. Therefore, choosing a suitable technique to test EGFR mutational status is crucial to warrant a valid result in a short turnaround time using the lowest possible amount of tissue material.The Idylla™ EGFR Mutation Test is a simple, fast and reliable method designed for the detection of EGFR mutations from formalin-fixed paraffin-embedded samples. The aim of this study was the Clinical Performace Evaluation of the Idylla™ EGFR Mutation Test on the Idylla™ System.Methods: EGFR mutational status was determined on 132 archived formalin-fixed paraffin-embedded tissue sections with Idylla™ technology. Results were compared with the results previously obtained by routine method in the reference lab (Therascreen® EGFR RGQ PCR v2, Qiagen in Molecular Pathology lab, Hospital Universitario Virgen del Rocío de Sevilla).Results: the overall agreement between results obtained with the Idylla™ EGFR Mutation Test and the Comparator test method was 95.38% (with 1-sided 95% lower limit of 91.7%) showing Positive Diagnostic Agreement of 93.22% and Negative Diagnostic Agreement of 97.18%, with a Limit Of Detection ≤5%. Conclusions: the Idylla™ EGFR Mutation Test passed its clinical validity performance characteristics for accuracy.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results